How well the shingles vaccine works for adults with immune-mediated systemic inflammatory diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study measures anti-VZV seroconversion after routine vaccination with the recombinant shingles vaccine given as two doses two months apart in adults with immune-mediated systemic inflammatory diseases followed at Hôpital Bichat. Antibody response will be measured using serum samples collected during standard hospitalizations or follow-up visits in the CHU Bichat immunology laboratory, with no extra study visits required. Clinical and biological data will be collected to identify factors linked to vaccine response, vaccine tolerance, and underlying disease activity. Eligible patients include those vaccinated between June 2025 and June 2026 who have at least one available serum sample and have received the first vaccine dose.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years of age being managed for MIMI, including
* Systemic lupus
* Gougerot-Sjögren's syndrome
* Systemic scleroderma
* Mixed connectivitis
* Inflammatory myositis
* Systemic sarcoidosis
* Systemic vasculitis (necrotizing vasculitis and giant cell arteritis)
* Behçet's disease
* Adult Still's disease
* IgG4-associated disease
* Autoimmune cytopenias (autoimmune hemolytic anemia, immunological thrombocytopenic purpura, Evans syndrome)
* Susac syndrome
* Followed in the internal medicine department of Hôpital Bichat, Paris
* Justifying VZV vaccination due to immunosuppression or age over 65.
* Vaccinated as part of care between June 2025 and June 2026
* Regardless of history of shingles
* With a serum sample available for analysis
* Having received at least the first dose of the vaccine regimen (in hospital or in the community)

Exclusion Criteria:

* Evolving cancer, with or without treatment (chemotherapy, immunotherapy, etc.)
* History of VZV vaccination (live or recombinant)
* Patient who has had an allergic reaction to a vaccine
* Pregnancy
* Patient under legal protection, guardianship or trusteeship
* Not affiliated to a social security scheme (general or CMU)
* Patient unable to understand research information
* Absence of non-opposition

Where it's running

• Hôpital Bichat
  Paris, France Recruiting

Study contacts

• Study coordinator: Tiphaine Goulenok, MD
• Email: tiphaine.goulenok@aphp.fr
• Phone: 0140257289

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UK CARDIO-IMID registry for heart disease in people with immune-mediated inflammatory conditions

  This registry will see if routine blood heart markers can predict future heart problems in people with immune-mediated inflammatory diseases.

  Recruiting at 2 sites University of Manchester · Edinburgh, Scotland and 1 other locations · NCT06478277

• Understanding how intravenous acyclovir works in children with cancer

  This study is trying to understand how the drug acyclovir works in children with cancer to see if it can help protect them from serious herpesvirus infections.

  Recruiting University of Pisa · Trieste, TS · NCT05198570

• Lyophilized herpes zoster mRNA vaccine given to adults 40 and older

  This trial tests two injections of ABO1108 versus placebo to see if the vaccine protects adults aged 40+ from shingles and how safe and workable it is.

  Recruiting at 4 sites Phase 3 Suzhou Abogen Biosciences Co., Ltd. · Jinan and 3 other locations · NCT07817108

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.